Trial Profile

A Phase II Trial of Multisite Stereotactic Ablative Radiotherapy (SABR) Combined With Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fruquintinib (Primary) ; Tislelizumab (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms RIFLE

Most Recent Events

09 Sep 2024 According to HUTCHMED media release, the data of this trial will be presented at the the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain.
04 Jun 2024 Results (n=34) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
23 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL and online.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com